Standard antibiotic prophylaxis (BAPTIST trial)

Standard antibiotic prophylaxis (BAPTIST trial) refers to the control intervention arm of the BAPTIST clinical trial (NCT05502380), a Phase 3 randomized superiority trial led by Balgrist University Hospital. This protocol represents the current evidence-based standard of care for preventing surgical site infections (SSI) in high-risk orthopedic surgeries, such as tumor resections, spine surgeries, and open fractures. The regimen typically involves one to three intravenous doses of cefuroxime (1.5 g, or 3 g for obese patients); in cases of penicillin or cephalosporin allergy, vancomycin (1 g) or clindamycin (600 mg) is used. The trial compares this standard approach against a broad-spectrum prophylaxis regimen consisting of a single-shot combination of vancomycin and gentamicin.

Other names

Standard antibiotic prophylaxis-Balgrist University Hospital-surgical site infectionStandard antibiotic prophylaxisBAPTIST trial standard arm